Hot verticals: the seven technology sectors that concentrate venture capital

What it is

The Hot Verticals beat tracks seven technology sectors where venture capital concentrates in ways that move markets and set regulatory agendas: fintech, climate tech, defense tech, biotech and health, crypto and web3, robotics and hardware, and deep tech. Funding rounds in 2024-2026 will determine which payment rails, energy systems, drug molecules, and robots reach commercial scale by the end of the decade. Capital allocation precedes product, regulation, and geopolitical leverage, which is why a reader in Nairobi or Jakarta tracks this beat as closely as one in San Francisco. AI crosses through all seven verticals as enabler and disruptor; defense tech and deep tech overlap in quantum sensing, while fintech and crypto compete for the same payments infrastructure.

History

Fintech emerged as a distinct VC category around 2010 on mobile payments and neobanks. Climate tech had a first wave, "cleantech 1.0," peaking near US$8 billion per year in 2008, that collapsed on hardware economics; the second wave is software-enabled and policy-backed by the US Inflation Reduction Act (August 2022). Defense tech opened to venture capital after Palantir's 2003 US founding and Anduril's 2017 launch; Russia's February 2022 invasion of Ukraine normalized private venture funding of autonomous weapons. Biotech has drawn venture capital since Genentech's 1976 US founding; AI-native drug discovery arrived as a distinct thesis around 2019. Crypto followed bull cycles in 2013, 2017, and 2021, collapsed with FTX's November 2022 failure, and recovered after the US SEC approved Bitcoin spot ETFs in January 2024. Robotics moved from warehouse automation (Amazon's US$775 million acquisition of Kiva Systems in 2012) to humanoid robots by 2024-2026, with China's embodied AI sector accelerating separately. Deep tech, covering quantum computing, fusion, and novel materials, emerged as a distinct VC category around 2018.

Current state

Global VC hit a record US$330.9 billion in Q1 2026 (KPMG Venture Pulse), more than doubling Q4 2025's US$128.6 billion. Full-year 2025 US VC reached US$339.4 billion, second-highest on record; AI/ML captured 65.6% of deal value (PitchBook-NVCA). Climate tech attracted US$77.3 billion in private and public equity globally in 2025 (BloombergNEF), up 53%, though venture funding for early-stage climate startups fell for a third year as growth concentrated in growth equity. US defense tech company Shield AI raised US$2.3 billion in Q1 2026. China's embodied AI sector produced two robotics companies each valued at roughly US$2.8 billion in a single day in June 2026. Biotech and crypto infrastructure remain active across geographies as of mid-2026.

Relationships

Singapore's Qashier and India's CRED, whose US$900 million Series H included a Meta stake, show different maturity points in the global fintech arc: small-business tooling in Southeast Asia versus platform-scale consumer finance in South Asia. Climate tech intersects with fintech at carbon credits and green bonds, and with deep tech in grid software and battery chemistry. Africa's EV battery-swap operator Spiro (US$270 million, mid-2026) illustrates how climate tech in emerging markets shifts toward blended development finance. Defense tech and deep tech overlap in quantum sensing, hypersonics, and directed energy. France's Alan (€480 million at €5.5 billion, June 2026) sits at the healthtech end of the biotech arc, alongside AI drug discovery platforms. Nigeria's Daya, building stablecoin payment rails for African businesses, shows how crypto and fintech converge where legacy banking is thin. China's embodied AI megarounds of June 2026 show how state-linked capital and private venture combine in robotics differently from the US humanoid race.

What to watch

• Whether the US Inflation Reduction Act's clean energy incentives survive legislative revision, reshaping climate tech funding and blended-finance models globally by 2027.
• Europe's MiCA regulation (live end-2024), the first major regional crypto framework; how startups adapt will set compliance norms for Asia and Latin America.
• Humanoid robot commercial deployments: US and Chinese startups target revenue-generating manufacturing deployments in 2026-2027, the milestone that would validate a decade of hardware investment.
• Biotech's AI-discovery pipeline: the first AI-native drug molecules entering Phase 3 clinical trials (targeted 2026-2028) will validate or deflate the investment thesis for a cohort of drug discovery startups.
• Deep tech's exposure to LP pullback: with US VC fundraising at a decade-low in 2025, startups requiring 10-year capital cycles face the greatest funding risk.